Vol 75, No 2 (2024)
Original paper
Published online: 2024-03-19

open access

Page views 452
Article views/downloads 258
Get Citation

Connect on Social Media

Connect on Social Media

Original paper

Endokrynologia Polska

DOI: 10.5603/ep.99111

ISSN 0423–104X, e-ISSN 2299–8306

Volume/Tom 75; Number/Numer 2/2024

Submitted: 25.01.2024

Accepted: 03.02.2024

Early publication date: 19.03.2024

Circulating levels of irisin and Meteorin-like protein in PCOS and its correlation with metabolic parameters

Katarzyna Paczkowska1Joachim Sobczuk2Katarzyna Zawadzka1Diana Jędrzejuk1Agnieszka Zembska1Jacek Konieczny3Dorota Kaszubkiewicz-Wardęga4Marek Bolanowski1Jacek Daroszewski1
1Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland
2Department of Endocrinology, Diabetes and Isotope Therapy, University Clinical Hospital, Wroclaw, Poland
3CodeAI, Poznan, Poland
4 2nd Department of Gynaecology and Obstetrics, University Clinical Hospital, Wroclaw, Poland

Katarzyna Paczkowska, Department of Endocrinology, Diabetes and Isotope Therapy, Wybrzeże Pasteura 4, 50–367 Wrocław, Polska; tel.: +48 71 784 25 46; e-mail: katarzyna.paczkowska@student.umw.edu.pl

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially

Introduction: Research on obesity, which results from excessive food consumption and sedentary lifestyle, has focused on increasing energy expenditure. Recently, muscle tissue is being investigated as an endocrine active organ, secreting molecules called myokines. Multiple studies have been performed to assess myokine levels in various disorders, including polycystic ovary syndrome (PCOS) and metabolic syndrome. Irisin and Meteorin-like protein (Metrnl) are particles which, among others, are suggested to play an important role in adipose tissue browning and improving insulin sensitivity.
Material and methods: The study population consisted of 31 women with PCOS and 18 healthy individuals. PCOS was diagnosed based on revised 2003 Rotterdam criteria. Multiple anthropometrical, hormonal, and biochemical parameters were assessed, including oral glucose tolerance test and body composition with dual energy X-ray absorptiometry. Serum levels of irisin and Metrnl were measured by enzyme-linked immunosorbent assay (ELISA).
Results: There were no differences between the PCOS and control groups according to age, body mass index (BMI), waist-to-hip ratio (WHR), fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR), or body mass composition. Assessment of Metrnl and irisin concentrations revealed no significant differences between PCOS and healthy women. The irisin level was negatively correlated with BMI, body fat mass, fasting glucose, and insulin concentrations. No relationship between Metrnl level and metabolic parameters was found.
Conclusions: Although irisin seems to be a promising biomarker, inconsistent research limits its value in clinical use in the assessment or treatment of obesity. Metrnl level was not affected in the study population, but it might be connected to the severity of metabolic disturbances. (Endokrynol Pol 2024; 75 (2): 199206)
Key words: irisin; Meteorin-like protein; Metrnl; myokines; metabolic disturbances; obesity; PCOS


The global prevalence of obesity has nearly tripled during the past 4 decades, and this trend has been observed in different regions worldwide [1]. As a result, between 1990 and 2015 an increase in deaths and disability rates related to overweight and obesity was estimated of approximately 28% and 35%, respectively [2]. Obesity is associated with numerous health issues, including diabetes mellitus, cardiovascular disease, sleep apnoea, depression, and bone metabolism disturbances [3, 4], which are related to changes in adipose metabolism [5]. It was found that among overweight and obese women, approximately a quarter of them suffer from polycystic ovary syndrome (PCOS) [6].

PCOS is one of the most common endocrinopathies among reproductive-age women [7]. Clinical presentation varies between patients; however, reproductive, dermatological, metabolic, and psychological issues may be present [8]. Polycystic ovary syndrome, as a condition affecting women’s metabolic health from young age, might be a biological model of insulin resistance and early metabolic disturbances.

In the past, skeletal muscle function was thought to be mainly associated with locomotion and body posture. Recently, studies revealed that myofibers, in response to exercise, express and release different factors that have paracrine and endocrine effects [9]. This group of molecules, called “myokines”, includes irisin and Meteorin-like protein (Metrnl). Research on obesity, resulting from excessive food consumption and sedentary lifestyle, has focused on increasing energy expenditure, and muscle tissue is being investigated as an endocrine active organ.

Irisin was firstly described by Boström et al. in 2012. It is a product of the proteolytic cleavage of fibronectin type III domain containing 5 (FNDC5) by as-yet-unknown enzymes. [10]. It was revealed that FNDC5 expression was higher in muscles and organs composed of muscles, such as the tongue, rectum, or heart and was significantly lower in the adipose tissue [11].

Irisin was found to be involved in various metabolic pathways; it also has an influence on glucose metabolism in skeletal muscle cells through the AMPK pathway [12], induces the translocation of GLUT4 to the cell membrane, stimulates glucose uptake [13], and downregulates the expression of genes involved in gluconeogenesis and glycogenolysis. [14] Moreover, a positive influence of irisin on the nervous system was suggested, and this myokine is suspected to be an important particle in exercise-induced neuroprotection [15, 16]. One of the main possible roles of irisin is promoting energy expenditure through influencing the differentiation of white adipose tissue (WAT) into brown adipose tissue (BAT) [17]. Circulating irisin concentration has a day-night secretion rhythm [18] and increases shortly after acute exercise [14]; however, no statistical differences were reported in regard to irisin levels between people with low, moderate, or high physical activity [18]. Additionally, it was reported that the irisin level is not related to dietary habits and does not change after meal consumption [18].

Expression in various tissues and circulating levels of irisin have been investigated in numerous disorders, including obesity, diabetes mellitus, neuropsychiatric disorders, and cancers. Circulating levels of irisin tend to be decreased in several types of cancer [19]; however, higher expression of irisin in breast cancer tissue was reported as a good prognostic marker [20]. Although the results from studies related to metabolic disorders are inconclusive, some research suggests higher concentrations of irisin in individuals with obesity or DM, and this phenomenon was explained as possible “irisin resistance” [21].

Metrnl, also called subfatin, is a particle with approximately 40% similarity to Meteorin, according to amino acid sequence [22], but the physiological functions of those proteins differ. Meteorin is a factor that plays a role in neurogenesis [23], while Metrnl was suggested to be involved in maintaining metabolic homeostasis [24]. Expression of Metrnl was found in various organs, including liver, spleen, heart, skin, fat, and muscle tissue [25]. Similarly to Irisin, the expression of Metrnl in adipose and muscle tissue is enhanced by physical exercise and exposure to cold. Moreover, there is evidence linking Metrnl with an improvement in insulin sensitivity, an increase in energy expenditure, and positive regulation of thermogenic gene expression associated with promoting browning of adipose tissue. Moreover, an anti-inflammatory function of Metrnl was reported [26]. In the muscle tissue, Metrnl improves insulin sensitivity through AMP-activated protein kinase (AMPK) or peroxisome proliferator-activated receptor δ (PPARδ) [27]. On the other hand, it was suggested that Metrnl concentration is altered in several disorders, including obesity, diabetes mellitus type 2, and cardiovascular disease [28–30]. Additionally, Metrnl has been investigated as a diagnostic biomarker or therapeutical target in cardiometabolic disorders [31].

The aim of the study was to assess circulating levels of irisin and Metrnl, 2 myokines with potentially similar physiological functions, in women with PCOS in relation to severity of metabolic disturbances.

Material and methods

Description of the study population

The study population included 49 Caucasian women: 31 with PCOS and 18 healthy individuals. PCOS was diagnosed based on the revised 2003 Rotterdam criteria after excluding related disorders [32]. Among inclusion criteria for whole study population were as follows: age between 18 and 40 years, no history of hypoglycaemic or hypolipidaemic treatment, and not using hormonal contraception for at least 6 months prior to tests. Exclusion criteria were as follows: pregnancy, diabetes mellitus (DM), history of bariatric surgery, chronic disease with therapy that has an influence on hormonal secretion, loss of 10% or more body weight in the 3 months prior to the tests. Besides those mentioned above, an additional criterion for the control group was no history of menstrual irregularity in the past 3 years.

Patients were asked to perform their usual daily physical activity for the 7 days prior to tests.

The research was conducted under the Declaration of Helsinki, and approval was obtained from the Ethical Committee of Wroclaw University of Medical Sciences (approval no KB-566/2020). All individuals who participated in the study provided written consent.

Anthropometrical parameters

Weight, height, and waist and hip circumferences were measured with standard techniques. Body mass index (BMI) was calculated with the formula:

BMI = weight [kg]/height2 [m2].

Overweight was defined as BMI25, and obesity was diagnosed in patients with BMI equal to or higher than 30, in accordance with World Health Organisation (WHO) criteria [33]. Taking into consideration the BMI criterion, the study population was divided into 2 groups: normal-weight (NW) or overweight/obese (OW).

Waist circumference (WC) greater than or equal to 80 cm was a criterium to define central obesity. Consequently, the group of women with abdominal obesity (AbO+) was separated from the study population.

Hormonal and biochemical assessment

All participants were examined, and all tests were performed in follicular phase, between the third and sixth day of the menstrual cycle. Blood samples were taken after overnight fasting; biochemical and hormonal assessments were performed with commercially available methods.

An oral glucose tolerance test with 75 g of glucose was performed, and glucose and insulin levels were measured before the test, and after 60 and 120 minutes. Homeostatic model assessment of insulin resistance (HOMA-IR) was used to assess insulin resistance, and HOMA IR was calculated with the standard formula:

HOMA-IR = insulin (µU/mL) × glucose (mmol/L)/22.5.

Insulin resistance was defined as HOMA-IR higher than 2.5 [34–36].

Body composition

Body composition was assessed with dual-energy X-ray absorptiometry (DXA). Hologic Discovery QDR Series densitometer (Hologic Incorp. USA, APEX, Windows 7 Professional system) was used for the measurements.

Irisin and Metrnl levels

Concentrations of serum irisin and Metrnl were measured in duplicate by ELISA using commercially available assays. The following kits were used: Irisin ELISA Kit (BioVendor, Czech Republilc, Catalogue No. RAG018R; sensitivity 1.0 ng/ml) and Human Meteorin-like protein (METRNL) ELISA Kit (Assay Genie, Ireland, Catalogue No. HUEB2525; sensitivity 7.3 pg/ml). Assays were carried out according to the manufacturers’ protocols.

Statistical analysis

Statistical analyses were performed with Statistica (TIBCO), version 13.3. The T-test and the Mann-Whitney U test were used to compare anthropometrical, biochemical, and hormonal parameters with irisin and Metrnl levels for normally and non-normally dispersed data, respectively. The correlations between parameters were assessed with Spearman correlation. In all analyses a p-value less than 0.05 was considered as statistically significant.


Comparison of basic anthropometrical, biochemical, and hormonal parameters between the PCOS and control groups is shown in Table 1. There were no differences in terms of age, BMI, WHR, fasting glucose, HOMA-IR, or body mass composition. In the study population PCOS women had significantly higher LH/FSH ratio and lower waist circumference.

Table 1. Comparison of anthropometric, biochemical, and hormonal parameters between polycystic ovary syndrome (PCOS) and control group





Age [years]

26.0 ± 3.6

28.0 ± 5.6


BMI [kg/m2]

26.17 ± 7.41

28.92 ± 7.10


Waist circumference [cm]

82.0 ± 15.6

93.9 ± 16.7



0.80 ± 0.08

0.83 ± 0.06


Fasting glucose [mg/dL]

84.5 ± 8.0

86.1 ± 7.0



2.02 ± 1.63

2.50 ± 2.1


Body fat mass [kg]

26.74 ± 11.52

32.88 ± 12.23


Body lean mass [kg]

46.73 ± 10.4

49.98 ± 10.84


TCh [mmol/L]

4.54 ± 0.83

4.26 ± 1.29


HDL [mmol/L]

1.35 ± 2.07

1.36 ± 0.53


LDL [mmol/L]

2.62 ± 0.88

2.46 ± 0.88


TG [mmol/L]

0.95 ± 0.49

0.96 ± 0.74


TSH [µIU/mL]

1.50 ± 1.18

1.58 ± 0.67



1.42 ± 0.76

0.77 ± 0.35


Oestradiol [pg/mL]

49.59 ± 38.35

39.64 ± 16.43


Testosterone [ng/mL]

0.38 ± 0.16

0.32 ± 0.12


Androstenedione [ng/mL]

3.37 ± 1.37

2.94 ± 2.15


SHBG [nmol/L]

50.17 ± 26.19

44.96 ± 24.03


Statistical analysis revealed no significant differences in Metrnl or irisin levels between PCOS and healthy individuals as shown in Figures 1 and 2. However, irisin concentrations were in the narrow range of higher values.

Figure 1. Comparison of circulating Meteorin-like protein (Metrnl) level between polycystic ovary syndrome (PCOS) women and control group
Figure 2. Comparison of circulating irisin levels between polycystic ovary syndrome (PCOS) women and control group

The study population was divided into 2 groups: normal-weight and overweight or obese patients. The Metrnl level did not differ between those groups, as shown in Figure 3. Conversely, irisin concentrations differed between groups and were significantly higher in normal-weight women (Fig. 4).

Figure 3. Comparison of circulating Meteorin-like protein (Metrnl) levels between women with body mass index (BMI) equal or greater than 25 (OW) and normal-weight individuals (NW); p = 0.77
Figure 4. Comparison of circulating irisin levels between overweight or obese women (OW) and normal-weight individuals (NW); p < 0.05

Correlations between irisin and Metrnl levels and other parameters are presented in Table 2.

Table 2. Correlation coefficients between circulating irisin and Meteorin-like protein (Metrnl) levels and anthropometrical, biochemical, and hormonal parameters















Trunk fat mass



Whole body fat mass



Android/gynoid ratio



Trunk/limb fat mass ratio



Whole body fat/whole body mass






Fasting glucose



Total cholesterol











The irisin level was negatively correlated with BMI, body fat mass, android-to-gynoid ratio, and fasting glucose and positively correlated with HDL. There were no significant relationships between LH/FSH ratio, testosterone, or androstenedione and irisin concentrations.

The Metrnl concentration was not significantly associated with anthropometrical and biochemical parameters; the only correlation was a positive one with androstenedione level.


In the current study, irisin and Meteorin-like protein, 2 myokines engaged in regulation of energy metabolism, were measured in a PCOS population in comparison to healthy individuals. The myokines level was assessed with reference to various parameters, including body composition, to better understand influencing factors.

Analysis of irisin showed significantly higher concentrations in normal-weight women when compared to the group of overweight and obese individuals. Moreover, there were negative correlations between irisin level and BMI, fat mass, and the proportion between fat mass and whole body mass. A negative relationship was also found between circulating irisin and markers of carbohydrate metabolism: fasting glucose and HOMA-IR.

Literature data regarding a link between patients’ BMI and irisin concentrations are inconclusive. There are studies suggesting positive, negative, as well as no correlation between those parameters; however, more studies reported higher irisin levels in individuals with higher BMI [37]. At the same time, comparison of OW women to NW individuals in the PCOS population showed significantly higher irisin levels in the first group [38].

On the other hand, elevated levels of irisin in obese population were reported to be connected with lower risk of complications related to cardiometabolic disease [39]. It was also suggested that increased irisin concentration might improve insulin sensitivity and is connected to lower risk of insulin resistance [40]. PCOS is strongly associated with altered glucose metabolism and insulin secretion, and the coexistence of both factors in our study population, obesity and insulin resistance, might have an impact on irisin level.

Results from the present study did not show significant differences in irisin levels between the PCOS and control groups. Moreover, irisin and androgen concentrations were not correlated.

Literature data regarding irisin levels in PCOS are conflicting: higher, lower, and comparable concentrations were reported in the PCOS group when compared to the control group [41–45]. A meta-analysis summarising 8 studies suggested increased circulating irisin level in PCOS patients; however, differences were not seen when PCOS women were compared to BMI-matched healthy controls [46]. Results from our study are in agreement with this conclusion [46]; there were no differences in circulating irisin, but the PCOS and control groups were similar according to BMI and other anthropometrical parameters, including WHR and total fat mass, but not for WC. Comparable irisin concentrations between the study and control groups suggest an alteration of irisin level as a result of metabolic disturbances accompanying PCOS.

Research assessing the relationship between circulating androgens and irisin levels is limited, and the results are contradictory. On the one hand, it was reported that increased FAI corresponded with higher irisin levels, and FAI was assessed as the main prognostic factor of an elevated irisin level [47]; on the other hand, a negative correlation between circulating irisin level and LH, testosterone, and FAI was also presented in adolescents and adults with PCOS [43, 48], or no relationship was found in adult PCOS women [45].

An inconsistency between research regarding hyperandrogenaemia and irisin concentration might be partially caused by physiological connection of hyperandrogenaemia to insulin resistance. Increased levels of insulin enhance secretion of ovarian androgens [49] and inhibit the production of sex hormone-binding globulin [50]; what is more, androgen excess is correlated with the reduction of insulin sensitivity in skeletal muscles [51]. Our results did not show any relationship between androgen and irisin levels; however, significant correlation with the surrogate marker of insulin resistance was present.

In the current study there were no differences in Metrnl concentrations between women with and without PCOS or between normal-weight and obese or overweight individuals. Additionally, we found a correlation only between Metrnl and androstenedione level; there were no statistically significant relationships between Metrnl level and other hormonal, biochemical, or anthropometrical parameters.

As far as we know, Metrnl levels were analysed in PCOS only in 2 independent studies [52, 53]. In both studies significantly lower Metrnl levels were found in PCOS women when compared to healthy controls. In the first study, PCOS patients were divided into 2 groups: infertile patients and patients with recurrent pregnancy loss (RPL; defined as 2 or more losses of pregnancy before 20 weeks of gestation). Women with RPL have higher Metrnl serum levels when compared to infertile patients [52].

Inconsistency between our results and the data presented in the literature might be connected to dissimilarities in study design as well as to differences in the study population. In contrast to the first study [52], infertility or RPL were not an inclusion criterion for PCOS women in our study. Additionally, individuals who participated in our research did not take medicaments influencing glucose metabolism. In both the studies mentioned above, PCOS women had more strongly expressed insulin resistance, and a negative correlation between Metrnl and HOMA-IR was found [52, 53]. In the second study, the association between Metrnl and HOMA-IR was only observed in PCOS, not in the control group [53]. In our study, the PCOS women had insignificantly lower BMI and HOMA-IR when compared to controls. The differences in metabolic parameters between individuals participating in the studies might be related to the observed inconsistency in Metrnl levels in PCOS.

Existing findings regarding relationships between Metrnl concentrations and anthropometrical or biochemical parameters are inconclusive. Higher Metrnl expression was found in adipose tissue of obese children in comparison to lean individuals [54]; however, the studies related to the circulating level of Metrnl as a biomarker of obesity are inconsistent. Some research reported higher levels of Metrnl in overweight or obese patients when compared to a normal-weight population [55, 56], but conversely lower levels of Metrnl [57, 58] or no significant differences were also shown [52, 59]. At the same time, variations in circulating Metrnl were observed according to the presence of additional comorbidities, such as DM; higher levels of Metrnl in a diabetic population were not found in a non-diabetic group [56].

Moreover, studies are contradictory in terms of the relationship between circulating Metrnl level and metabolic parameters such as BMI, waist circumference, percentage of fat tissue, or insulin sensitivity. Negative correlations between Metrnl concentration and HOMA-IR [57], BMI [58, 60], visceral fat area, and TG and TCh levels [58, 61] were reported. On the other hand, a positive association between circulating Metrnl and BMI, TCh, TG, or HOMA-IR [55] and no relationship between Metrnl level and BMI was also described [61].

Taking into consideration the results from the present study and the literature data mentioned above, changes in circulating Metrnl might be connected to the severity of the metabolic disorders and hence not observed in milder disturbances of carbohydrate metabolism. What is more, duration of metabolic disease and number of complications or additional health issues might have an impact as well.

To the best of our knowledge, this is the first study comparing circulating irisin and Metrnl in the PCOS population; our study did not show a significant correlation between those myokines in this group.

Correlation between irisin and Metrnl levels was observed in one study of a group of patients with DM2 in the male population; this association was not confirmed in non-diabetic individuals and the female population of the study [56]. What is more, in a study comparing diabetic to non-diabetic individuals, Metrnl and irisin concentrations were not correlated when assessed in the whole study population [55].

Bearing in mind the similar physiological functions of irisin and Metrnl, no correlation between circulating levels of those myokines suggests individual roles rather than synergetic actions in physiological adaptation to metabolic disease. It is possible that different regulatory factors trigger the secretion of both myokines, and, as a result, their concentrations are unevenly affected by metabolic disturbances.

The most important limitation of the study was a small size of the groups. However, the results presented in this paper are the first phase of the study; the research continues and we intend to provide more comprehensive data of larger groups in the close future.


Although irisin seems to be a promising biomarker, inconsistent research limits its value in clinical use in the assessment or treatment of obesity. However, the correlation of irisin concentration with metabolic parameters suggests its important role in maintaining homeostasis. Metrnl level was not affected in the study population, but it might be connected to the severity of metabolic disturbances.

Data availability statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available.

Ethics statement

The research was conducted under the Declaration of Helsinki and obtained approval from the Ethical Committee of Wroclaw University of Medical Sciences (approval no. KB-566/2020).

Author contributions

Conceptualisation: K.P. and J.D.; methodology: K.P., A.Z., J.D.; validation: K.P. and J.D.; formal analysis: K.P., J.K., and J.D.; investigation: K.P., J.S., K.Z., D.J., A.Z.; resources: K.P., J.S., K.Z., D.J., D.K-W., and J.D.; data curation: K.P. and J.K.; writing—original draft preparation: K.P. and J.D.; writing—review and editing: K.P., J.D., D.J., A.Z., and M.B.; visualisation: K.P.; supervision: J.D.; project administration: K.P. and J.D.; funding acquisition: KP, JD, and MB. All authors have carefully read and accepted the manuscript.


This research was funded in part under the project financed from the funds granted by the Ministry of Science and Higher Education in the “Regional Initiative of Excellence” program for the years 2019–2022, project number 016/RID/2018/19, the amount of funding 11,998,121.30 PLN.

Conflict of interest

The authors have no conflicts of interest to declare.


  1. World Health Organization. Media Centre. Obesity and overweight: fact sheet. http://www.who.int/mediacentre/factsheets/fs311/en/ (10 April 2018).
  2. Afshin A, Forouzanfar MH, Reitsma MB, et al. GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1): 13–27, doi: 10.1056/NEJMoa1614362, indexed in Pubmed: 28604169.
  3. Kinlen D, Cody D, O’Shea D. Complications of obesity. QJM. 2018; 111(7): 437–443, doi: 10.1093/qjmed/hcx152, indexed in Pubmed: 29025162.
  4. Mendonça FM, Soares R, Carvalho D, et al. The impact of obesity on bone health: an overview. Endokrynol Pol. 2022; 73(6): 954–958, doi: 10.5603/EP.a2022.0063, indexed in Pubmed: 36519653.
  5. Kuryłowicz AE. Adipose tissue as a cause of endocrine dysfunction. Endokrynol Pol. 2023; 74(5): 468–479, doi: 10.5603/ep.95378, indexed in Pubmed: 37902012.
  6. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006; 166(19): 2081–2086, doi: 10.1001/archinte.166.19.2081, indexed in Pubmed: 17060537.
  7. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2: 16057, doi: 10.1038/nrdp.2016.57, indexed in Pubmed: 27510637.
  8. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10): 2447–2469, doi: 10.1210/clinem/dgad463, indexed in Pubmed: 37580314.
  9. Pedersen BK, Akerström TCA, Nielsen AR, et al. Role of myokines in exercise and metabolism. J Appl Physiol (1985). 2007; 103(3): 1093–1098, doi: 10.1152/japplphysiol.00080.2007, indexed in Pubmed: 17347387.
  10. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–468, doi: 10.1038/nature10777, indexed in Pubmed: 22237023.
  11. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738, doi: 10.1016/j.metabol.2012.09.002, indexed in Pubmed: 23018146.
  12. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6): 324–337, doi: 10.1038/nrendo.2016.221, indexed in Pubmed: 28211512.
  13. Lee HJ, Lee JOk, Kim N, et al. Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. Mol Endocrinol. 2015; 29(6): 873–881, doi: 10.1210/me.2014-1353, indexed in Pubmed: 25826445.
  14. Huh JY, Mougios V, Kabasakalis A, et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014; 99(11): E2154–E2161, doi: 10.1210/jc.2014-1437, indexed in Pubmed: 25119310.
  15. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18(5): 649–659, doi: 10.1016/j.cmet.2013.09.008, indexed in Pubmed: 24120943.
  16. Jodeiri Farshbaf M, Alviña K. Multiple Roles in Neuroprotection for the Exercise Derived Myokine Irisin. Front Aging Neurosci. 2021; 13: 649929, doi: 10.3389/fnagi.2021.649929, indexed in Pubmed: 33935687.
  17. Villarroya F. Irisin, turning up the heat. Cell Metab. 2012; 15(3): 277–278, doi: 10.1016/j.cmet.2012.02.010, indexed in Pubmed: 22405065.
  18. Anastasilakis AD, Polyzos SA, Saridakis ZG, et al. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab. 2014; 99(9): 3247–3255, doi: 10.1210/jc.2014-1367, indexed in Pubmed: 24915120.
  19. Pinkowska A, Podhorska-Okołów M, Dzięgiel P, et al. The Role of Irisin in Cancer Disease. Cells. 2021; 10(6), doi: 10.3390/cells10061479, indexed in Pubmed: 34204674.
  20. Cebulski K, Nowińska K, Jablońska K, et al. Expression of Irisin/FNDC5 in Breast Cancer. Int J Mol Sci. 2022; 23(7), doi: 10.3390/ijms23073530, indexed in Pubmed: 35408891.
  21. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12): 4899–4907, doi: 10.1210/jc.2013-2373, indexed in Pubmed: 24057291.
  22. Li Z, Gao Z, Sun T, et al. Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies. Front Immunol. 2023; 14: 1098570, doi: 10.3389/fimmu.2023.1098570, indexed in Pubmed: 36911663.
  23. Nishino J, Yamashita K, Hashiguchi H, et al. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J. 2004; 23(9): 1998–2008, doi: 10.1038/sj.emboj.7600202, indexed in Pubmed: 15085178.
  24. Alizadeh H. Meteorin-like protein (Metrnl): A metabolic syndrome biomarker and an exercise mediator. Cytokine. 2022; 157: 155952, doi: 10.1016/j.cyto.2022.155952, indexed in Pubmed: 35780711.
  25. Zheng SL, Li ZY, Song J, et al. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016; 37(5): 571–579, doi: 10.1038/aps.2016.9, indexed in Pubmed: 27063217.
  26. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014; 157(6): 1279–1291, doi: 10.1016/j.cell.2014.03.065, indexed in Pubmed: 24906147.
  27. Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018; 50(9): 1–11, doi: 10.1038/s12276-018-0147-5, indexed in Pubmed: 30213948.
  28. Timurkaan M, Timurkaan ES. Two Important Players for Type 2 Diabetes Mellitus: Metrnl and Asprosin. Clin Lab. 2022; 68(9), doi: 10.7754/Clin.Lab.2021.211015, indexed in Pubmed: 36125157.
  29. Rupérez C, Ferrer-Curriu G, Cervera-Barea A, et al. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction. J Exp Med. 2021; 218(5), doi: 10.1084/jem.20201206, indexed in Pubmed: 33635944.
  30. Miao ZW, Hu WJ, Li ZY, et al. Involvement of the secreted protein Metrnl in human diseases. Acta Pharmacol Sin. 2020; 41(12): 1525–1530, doi: 10.1038/s41401-020-00529-9, indexed in Pubmed: 32999412.
  31. Alizadeh H. Myokine-mediated exercise effects: the role of myokine meteorin-like hormone (Metrnl). Growth Factors. 2021; 39(1-6): 71–78, doi: 10.1080/08977194.2022.2032689, indexed in Pubmed: 35133923.
  32. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47, doi: 10.1093/humrep/deh098, indexed in Pubmed: 14688154.
  33. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894(I–XII): 1–253. http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/.
  34. Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt). 2011; 20(1): 37–43, doi: 10.1089/jwh.2010.2053, indexed in Pubmed: 21194310.
  35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419, doi: 10.1007/BF00280883, indexed in Pubmed: 3899825.
  36. Jahromi BN, Borzou N, Parsanezhad ME, et al. Associations of insulin resistance, sex hormone-binding globulin, triglyceride, and hormonal profiles in polycystic ovary syndrome: A cross-sectional study. Int J Reprod Biomed. 2021; 19(7): 653–662, doi: 10.18502/ijrm.v19i7.9476, indexed in Pubmed: 34458674.
  37. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine. 2018; 59(2): 260–274, doi: 10.1007/s12020-017-1476-1, indexed in Pubmed: 29170905.
  38. Li M, Yang M, Zhou X, et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015; 100(4): 1485–1493, doi: 10.1210/jc.2014-2544, indexed in Pubmed: 25675380.
  39. Bonfante IL, Chacon-Mikahil MP, Brunelli DT, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk. Arch Endocrinol Metab. 2017; 61(6): 524–533, doi: 10.1590/2359-3997000000305, indexed in Pubmed: 29412381.
  40. Shi X, Lin M, Liu C, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults. BMC Endocr Disord. 2016; 16(1): 44, doi: 10.1186/s12902-016-0123-9, indexed in Pubmed: 27473122.
  41. Adamska A, Karczewska-Kupczewska M, Lebkowska A, et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J. 2016; 63(12): 1107–1112, doi: 10.1507/endocrj.EJ16-0249, indexed in Pubmed: 27616010.
  42. Bostancı MS, Akdemir N, Cinemre B, et al. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2015; 19(23): 4462–4468, indexed in Pubmed: 26698239.
  43. Abali R, Temel Yuksel I, Yuksel MA, et al. Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. J Obstet Gynaecol. 2016; 36(7): 897–901, doi: 10.3109/01443615.2016.1174200, indexed in Pubmed: 27184575.
  44. Chang CL, Huang SYu, Soong YK, et al. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 2014; 99(12): E2539–E2548, doi: 10.1210/jc.2014-1180, indexed in Pubmed: 25029417.
  45. Pukajło K, Łaczmański Ł, Kolackov K, et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecol Endocrinol. 2015; 31(11): 907–911, doi: 10.3109/09513590.2015.1065482, indexed in Pubmed: 26172924.
  46. Cai X, Qiu S, Li L, et al. Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reprod Biomed Online. 2018; 36(2): 172–180, doi: 10.1016/j.rbmo.2017.10.114, indexed in Pubmed: 29217128.
  47. Li H, Xu X, Wang X, et al. Free androgen index and Irisin in polycystic ovary syndrome. J Endocrinol Invest. 2016; 39(5): 549–556, doi: 10.1007/s40618-015-0403-7, indexed in Pubmed: 26584566.
  48. Bacopoulou F, Athanasopoulos N, Efthymiou V, et al. Serum irisin concentrations in lean adolescents with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 88(4): 585–591, doi: 10.1111/cen.13555, indexed in Pubmed: 29368340.
  49. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83(6): 2001–2005, doi: 10.1210/jcem.83.6.4886, indexed in Pubmed: 9626131.
  50. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72(1): 83–89, doi: 10.1210/jcem-72-1-83, indexed in Pubmed: 1898744.
  51. Rincon J, Holmäng A, Wahlström EO, et al. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes. 1996; 45(5): 615–621, doi: 10.2337/diab.45.5.615, indexed in Pubmed: 8621012.
  52. Fouani FZ, Fadaei R, Moradi N, et al. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: A case-control study. PLoS One. 2020; 15(4): e0231943, doi: 10.1371/journal.pone.0231943, indexed in Pubmed: 32330176.
  53. Deniz R, Yavuzkir S, Ugur K, et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021; 41(2): 279–284, doi: 10.1080/01443615.2020.1758926, indexed in Pubmed: 32608281.
  54. Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017; 41(1): 112–119, doi: 10.1038/ijo.2016.180, indexed in Pubmed: 27748745.
  55. Wang K, Li F, Wang C, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019; 25: 2337–2343, doi: 10.12659/MSM.915331, indexed in Pubmed: 30928991.
  56. AlKhairi I, Cherian P, Abu-Farha M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019; 8(10), doi: 10.3390/cells8101283, indexed in Pubmed: 31635130.
  57. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018; 42(4): 919–922, doi: 10.1038/ijo.2017.268, indexed in Pubmed: 29081506.
  58. Ding X, Chang X, Wang J, et al. Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile. Front Endocrinol (Lausanne). 2022; 13: 938341, doi: 10.3389/fendo.2022.938341, indexed in Pubmed: 36133314.
  59. Chung HS, Hwang SY, Choi JuH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018; 136: 100–107, doi: 10.1016/j.diabres.2017.11.031, indexed in Pubmed: 29199003.
  60. Dadmanesh M, Aghajani H, Fadaei R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018; 13(9): e0204180, doi: 10.1371/journal.pone.0204180, indexed in Pubmed: 30212581.
  61. Du Y, Ye X, Lu A, et al. Inverse relationship between serum Metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020; 161: 108068, doi: 10.1016/j.diabres.2020.108068, indexed in Pubmed: 32044349.